Trading Report: Today, Maxim Group Downgraded Juno Therapeutics Inc (JUNO) Price Target to $34.00

Today, Maxim Group Downgraded Juno Therapeutics Inc (JUNO) Price Target to $34.00

Juno Therapeutics Inc (NASDAQ:JUNO) had its price objective reduced by investment analysts at Maxim Group from $50.00 to $34.00 in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective would indicate a potential upside of 50.71% from the stock’s current price.

Several other analysts have also recently commented on JUNO. FBR & Co set a $61.00 price target on shares of Juno Therapeutics and gave the stock a “buy” rating in a report on Friday, August 5th. Vetr cut shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price target for the company. in a report on Tuesday, August 16th. Standpoint Research started coverage on shares of Juno Therapeutics in a report on Thursday, August 25th. They set a “buy” rating and a $47.00 price target for the company. BTIG Research started coverage on shares of Juno Therapeutics in a report on Tuesday, August 30th. They set a “sell” rating and a $23.00 price target for the company. Finally, Zacks Investment Research upgraded shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 6th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Juno Therapeutics presently has an average rating of “Buy” and an average price target of $43.13.

Juno Therapeutics (NASDAQ:JUNO) opened at 22.56 on Wednesday. Juno Therapeutics has a 52 week low of $19.41 and a 52 week high of $57.82. The stock’s market capitalization is $2.31 billion. The stock has a 50 day moving average of $27.75 and a 200 day moving average of $33.02.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.05. The company had revenue of $20.80 million for the quarter, compared to analyst estimates of $10.98 million. The business’s revenue for the quarter was up 1200.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.26) EPS. On average, equities research analysts predict that Juno Therapeutics will post ($2.54) earnings per share for the current fiscal year.

In other news, EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the sale, the executive vice president now owns 48,640 shares in the company, valued at $1,174,169.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Hans Edgar Bishop sold 84,035 shares of the firm’s stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total transaction of $2,544,579.80. Following the completion of the sale, the chief executive officer now owns 2,518,537 shares in the company, valued at approximately $76,261,300.36. The disclosure for this sale can be found here.

Several large investors have recently made changes to their positions in JUNO. Vanguard Group Inc. increased its stake in shares of Juno Therapeutics by 14.8% in the second quarter. Vanguard Group Inc. now owns 5,471,650 shares of the biopharmaceutical company’s stock valued at $210,331,000 after buying an additional 707,140 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in shares of Juno Therapeutics by 40.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,663,180 shares of the biopharmaceutical company’s stock valued at $63,933,000 after buying an additional 475,709 shares during the last quarter. Lord Abbett & CO. LLC increased its stake in shares of Juno Therapeutics by 222.9% in the second quarter. Lord Abbett & CO. LLC now owns 688,876 shares of the biopharmaceutical company’s stock valued at $26,480,000 after buying an additional 475,553 shares during the last quarter. BlackRock Fund Advisors increased its stake in shares of Juno Therapeutics by 29.5% in the second quarter. BlackRock Fund Advisors now owns 1,964,403 shares of the biopharmaceutical company’s stock valued at $75,512,000 after buying an additional 446,978 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Juno Therapeutics by 36.1% in the second quarter. State Street Corp now owns 1,658,792 shares of the biopharmaceutical company’s stock valued at $63,764,000 after buying an additional 440,324 shares during the last quarter.

About Juno Therapeutics

Related posts

Leave a Comment